0.25 CME/CE Credit
Reducing the Risk of Alcohol-Associated Liver Disease - Frankly Speaking EP 292Guest: Jillian Joseph, MSPAS, PA-C
Music Credit: Richard Onorato
Alcohol use disorder is common, but effective medications to treat this disorder are not widely prescribed in the outpatient primary care setting, despite being available and having relatively good formulary coverage. Join us to hear how the use of medical treatment can decrease the incidence and progression of alcohol-associated liver disease.
Episode references and resource links:
Augustin G. L. Vannier et al, Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder, JAMA Network Open (2022). DOI: 10.1001/jamanetworkopen.2022.13014
Tetreault JM, O'Connor PG. Risky drinking and alcohol use disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis. UpToDate. Published April 28, 2022. Accessed June 11, 2022.
Holt SR, Tetrault, JM. Ambulatory Management of alcohol withdrawal. UpToDate. Published May 19, 2022. Accessed June 11, 2022.
Holt SR. Approach to treating alcohol use disorder. UpToDate. Published March 22, 2022. Accessed June 11, 2022.
Already listened on another platform?
- Identify criteria for diagnosing alcohol use disorder
- Discuss ways to treat alcohol use disorder
- Summarize evidence supporting the use of medications to reduce alcohol-associated liver disease
Frank J. Domino, MD
Professor, Family Medicine and Community Health,
University of Massachusetts Medical School, Worcester, MA
Jillian Joseph, MPAS, PA-C
Assistant Professor, Department of PA Studies, Massachusetts College of Pharmacy, Boston, MA
Clinical Instructor, Department of Family Medicine & Community Health, University of Massachusetts Medical School, Worcester, MA
The following financial relationships have been disclosed by faculty.
Frank J. Domino, MD
Has disclosed no relevant financial relationships.
Jillian Joseph, MPAS, PA-C
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credits
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supporters and Partners
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.